24 treatment-naïve RRMS patients participated in a 1 year prospective safety study. There were no differences were identified between the two treatment groups with respect to patient-reported adverse events or laboratory abnormalities. The combination treatment regimen of interferon beta-1a and mycophenolate was well tolerated.
The investigators conclude: “Despite the small sample size, therapeutic trends were observed in favor of combination therapy. An adequately powered controlled trial of mycophenolate in MS appears warranted.”
I couldn’t agree more with the investigators; given the current dogma concerning the autoimmune pathogenesis of MS, mycophenolate should be given a chance. The problem is that with the imminent launch of several oral therapies, will it be possible to design an affordable trial to test mycophenolate in RRMS? I suspect not!